Literature DB >> 26683632

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Ali Ghasemzadeh1, Trinity J Bivalacqua2, Noah M Hahn3, Charles G Drake4.   

Abstract

Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26683632      PMCID： PMC4825862          DOI： 10.1158/1078-0432.CCR-15-1135

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  81 in total

Review 1.  Bladder cancer: epidemiology, diagnosis, and management.

Authors:  Chris Leo Pashos; Marc F Botteman; Benjamin Lewis Laskin; Alberto Redaelli
Journal:  Cancer Pract       Date:  2002 Nov-Dec

2.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Systemic chemotherapy for advanced bladder cancer: update and controversies.

Authors:  Jorge A Garcia; Robert Dreicer
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

6.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Authors:  Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

9.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Authors:  Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

10.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226
View more
  27 in total

Review 1.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

2.  Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.

Authors:  Ruohua Chen; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

Review 3.  Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.

Authors:  Ariel E Marciscano; Ravi A Madan
Journal:  Curr Treat Options Oncol       Date:  2018-03-08

4.  Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Authors:  Max Kates; Thomas Nirschl; Nikolai A Sopko; Hotaka Matsui; Christina M Kochel; Leonardo O Reis; George J Netto; Mohammad Hoque; Noah M Hahn; David J McConkey; Alex S Baras; Charles G Drake; Trinity J Bivalacqua
Journal:  Cancer Immunol Res       Date:  2017-06-06       Impact factor: 11.151

5.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

Review 6.  Immunobiology and immunotherapy in genitourinary malignancies.

Authors:  Marinos Tsiatas; Petros Grivas
Journal:  Ann Transl Med       Date:  2016-07

7.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

Review 8.  Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Xue Li; Minghuan Li; Zhen Lian; Hui Zhu; Li Kong; Ping Wang; Jinming Yu
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

Review 9.  Immunotherapy for metastatic renal cell carcinoma.

Authors:  Susanne Unverzagt; Ines Moldenhauer; Monika Nothacker; Dorothea Roßmeißl; Andreas V Hadjinicolaou; Frank Peinemann; Francesco Greco; Barbara Seliger
Journal:  Cochrane Database Syst Rev       Date:  2017-05-15

Review 10.  Current status and future perspectives of immunotherapy in bladder cancer treatment.

Authors:  Zhangsong Wu; Jinjian Liu; Ruixiang Dai; Song Wu
Journal:  Sci China Life Sci       Date:  2020-08-26       Impact factor: 6.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.